FDA Approves Updated 2026-27 COVID-19 Vaccines Targeting XFG Variant

On August 27, the U.S. Food and Drug Administration (FDA) granted approval for updated COVID-19 vaccines from Moderna, Pfizer-BioNTech and Novavax-Sanofi. The new formulations target the XFG subvariant of the JN.1 lineage for the 2026-27 respiratory-virus season. Eligibility mirrors the previous year: adults 65 + and younger individuals with at least one high-risk condition. Age-specific authorizations are: Moderna’s Spikevax for ages 6 months and up, mNEXSPIKE for ages 12 and up, Pfizer-BioNTech’s Comirnaty for ages 5 and up; Novavax-Sanofi for ages 12 and up. Manufacturers say doses will begin shipping within days, with pharmacy and clinic distribution expected shortly.

WXLV - Winston-SalemUsNews and World ReportPharmaphorumThe Guardian

The 2025-26 season saw the FDA recommend targeting the LP.8.1 subvariant of JN.1. Since the shift to risk-based guidance, the CDC now advises “individual-based decision making.” A March court ruling that invalidated Health Secretary Robert F. Kennedy Jr.’s appointment of new CDC advisory panel members has left the panel in legal limbo, creating uncertainty over formal vaccine recommendations and insurance coverage requirements.

The Guardian

• Moderna CEO Stéphane Bancel cited up to 2.3 million outpatient visits and 250,000 hospitalizations from COVID-19 in the United States last year.

Pharmaphorum

• CDC data for the week ending August 15 showed a test-positivity rate approaching 5 %, the highest since early February, with increases reported in every state.

CNN

• Sequencing submissions remain low, but as of early July the XFG.1.1 subvariant was identified as the predominant strain.

UsNews and World Report

• The updated shots cover roughly 30 % of the U.S. population based on age and comorbidity criteria (CDC modeling).

The Guardian

• Pfizer-BioNTech announced that the newly approved Comirnaty XFG will “begin shipping immediately” and be available in pharmacies, hospitals and clinics within days.

WXLV - Winston-Salem

• Moderna indicated its Spikevax and mNEXSPIKE formulations will be “available soon,” noting warnings for rare myocarditis and pericarditis cases, primarily in males 12-24 years old.

WXLV - Winston-Salem

• The CDC reported that overall COVID-19 hospitalizations remain “very low,” though it warned of possible summer surges if a variant evades existing immunity.

United Press International (UPI)

• The FDA’s guidance emphasizes matching vaccine composition to circulating strains, specifically the XFG subvariant, to improve protective efficacy for the upcoming season.

WXLV - Winston-Salem

Sources differ on the precise strain focus. Most outlets state the vaccines target the XFG subvariant, while one report notes Pfizer’s formulation also targets the LP.8.1 strain. The CDC has not issued an official recommendation for the 2026-27 season, leaving insurer coverage unclear. No public data are available on the manufacturers’ projected production volumes.

UsNews and World Report

• “COVID-19 remains a serious public health threat, responsible for up to 2.3 million outpatient visits and 250,000 hospitalizations in the U.S. last year alone,” — Moderna CEO Stéphane Bancel

Pharmaphorum

Pfizer-BioNTech and Moderna expect distribution to reach pharmacies and clinics in September, pending final logistics. The CDC is expected to issue an individual-risk recommendation later in the season, which will clarify insurance coverage expectations. Monitoring of XFG prevalence and COVID-19 activity will continue through CDC surveillance dashboards.

United Press International (UPI)